COMMUNIQUÉS West-GlobeNewswire

Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma
17/09/2018
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today [...]
Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast
17/09/2018
NEW YORK and MELBOURNE, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all necessary approvals, [...]
PotNetwork Holdings' Diamond CBDShowcases Growing Product Line in Miami at 2018 World Vapor Expo
17/09/2018
FT. LAUDERDALE, Fla., Sept. 17, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- PotNetwork Holdings, Inc. (OTC Pink: POTN ) is pleased to announce that its wholly owned subsidiary, Diamond CBD , Inc., drew a substantial [...]
Genetic Technologies Invited to Establish a Market Presence in Hainan, China
17/09/2018
MELBOURNE, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Hainan Resort Software Community(“ HRSC ”) has on behalf of Hainan Ecological Smart City Group (“ HESCG ”) formally extended an invitation to Genetic Technologies [...]
Creation of novel medicines and better patient care for the future in an ecosystem
17/09/2018
ORION CORPORATION PRESS RELEASE 17 SEPTEMBER 2018 Creation of novel medicines and better patient care for the future in an ecosystem Orion Corporation has together with selected university research groups and other [...]
OV - Updated LiPlaCis data positions LiPlaCis and its DRP for an FDA Breakthrough Therapy designation application for breast cancer
17/09/2018
Hoersholm, Denmark, September 17, 2018 - Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ("OV" or "the Company") announce the fourth update from the ongoing LiPlaCis ® Phase 2 study. In the ongoing study, the [...]
Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board
17/09/2018
Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading [...]
Shire plc: Rule 2.9 Announcement
17/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 17 September 2018 [...]
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
17/09/2018
Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos, including webcasts and [...]
Curetis To Attend Key Investor and Scientific Conferences In The Fourth Quarter 2018
17/09/2018
Curetis To Attend Key Investor and Scientific Conferences In The Fourth Quarter 2018 Amsterdam, the Netherlands, San Diego, CA, USA and Holzgerlingen, Germany , September 17, 2018 , 01:00 a.m. EST -- Curetis N.V. (the [...]
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
17/09/2018
Favorable safety and tolerability consistent with efgartigimod clinical trials to date Clinically meaningful platelet count improvements showed clear separation from placebo at increasing response thresholds Plan to [...]
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology
17/09/2018
BEIJING, China and CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
VBI Vaccines Responds to Unfounded Allegations in Globes Article
16/09/2018
CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali [...]
VBI Vaccines Responds to Unfounded Allegations in Globes Article
16/09/2018
CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali [...]
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
15/09/2018
- Single-doses were well-tolerated and showed reduction in pruritus - - Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis - HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE [...]
Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
15/09/2018
Positive Phase 3 results presented for Dupixent ® (dupilumab) show significant improvement on multiple measures of disease severity in adolescents with moderate-to-severe atopic dermatitis Results on skin clearing, itch [...]
Sanofi : Les résultats positifs de phase III concernant Dupixent® (dupilumab)
15/09/2018
Les résultats positifs de phase III concernant Dupixent ® (dupilumab) montrent une amélioration significative de plusieurs mesures de la sévérité de la maladie chez des adolescents atteints de dermatite atopique modérée [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/09/2018
BOTHELL, Wash., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
PUF Ventures Perfectly Positioned to Benefit from a Renewed Enthusiasm in the Canadian Cannabis Space
14/09/2018
VANCOUVER, British Columbia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Enthusiasm has returned to the legal cannabis space in Canada and PUF Ventures Inc. (CSE: PUF) (OTC: PUFXF), a late stage ACMPR license candidate, appears [...]

Pages